Nektar Therapeutics (NKTR) announced after the bell Tuesday that its Phase 3 study of NKTR-102 in patients with advanced breast cancer did not achieve statistical significance.
Nektar Therapeutics gapped open sharply lower Wednesday morning, but traded in a range for the majority of the session. The stock closed down by 1.62 at $12.51 on the highest volume of the year. Nektar Therapeutics closed testing support, trading at a 1-week low.
For comments and feedback contact: editorial@rttnews.com
Business News